Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | GBA1 | P04062 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | PLEC | Q15149 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926652 | 0.89 | L3MBTL1 (0.53) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9926711 | 0.83 | KDM4E (0.75) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9926648 | 0.82 | KDM4E (0.73) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9926641 | 0.82 | GBA1 (0.73) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL17739944 | 0.78 | GBA1 (0.71) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9926663 | 0.77 | KDM4E (0.65) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL17739844 | 0.75 | GBA1 (0.67) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL15992490 | 0.75 | GBA1 (0.73) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL15993458 | 0.75 | KDM4E (0.63) | KDM4EMAPTALDH1A1HPGDL3MBTL1 | |
| SCHEMBL9926736 | 0.75 | GBA1 (0.77) | KDM4EMAPTALDH1A1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | claimed |
| EP-2649075-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2018-04-25 | — | — | EP | claimed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | claimed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | claimed |
| EP-3366688-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2022-02-09 | — | — | EP | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-23 | — | — | US | disclosed |
| US-20180263988-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2018-09-20 | — | — | US | disclosed |
| EP-3366688-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-9974789-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-05-22 | — | — | US | disclosed |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | US HEALTH (US) | 2016-12-01 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353117-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2012078855-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180263988-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885MAPT 2835/4885ALDH1A1 2433/4885 |
| US-20160346284-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885MAPT 2835/4885ALDH1A1 2433/4885 |
| US-20140249145-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS | GBA1, GAA, GBA3 | KDM4E 2174/4885MAPT 2835/4885ALDH1A1 2433/4885 |
| US-10925874-B2 | Substituted pyrazolopyrimidines as glucocerebrosidase activators | GBA1, GAA, GBA3 | KDM4E 2174/4885MAPT 2835/4885ALDH1A1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.